Literature DB >> 6968711

The electrophoretic mobility of alpha 1-antitrypsin in sputum and its relationship to protease inhibitory capacity, leucocyte elastase concentrations and acute respiratory infection.

D Burnett, R A Stockley.   

Abstract

The electrophoretic mobility of uncomplexed alpha 1-antitrypsin was studied in the sol phase of sputum from 14 patients with chronic bronchitis. The mobility of alpha 1-antitrypsin in the sputum of each subject was reduced compared to the mobility in serum (mean sputum value = 71.1% of albumin mobility; mean serum value = 78.5% of albumin mobility). This reduction in alpha 1-antitrypsin mobility was most significant in the sputum samples of patients with chest infections which contained free elastolytic activity (mean value in cases where no enzyme activity was found = 74.9%; in cases with enzyme activity = 66.1%, 2P < 0.01). There was a significant inverse relationship between alpha 1-antitrypsin mobility in sputum and concentration of immunoreactive leucocyte elastase (r = -0.739, 2P < 0.01). The addition of trypsin to the sputum samples showed failure to inhibit the enzyme despite the apparant presence of sufficient uncomplexed alpha 1-antitrypsin in these samples, suggesting this alpha 1-antitrypsin was non-functional. Proteolytic enzymes can inactivate alpha 1-antitrypsin with a reduction in its electrophoretic mobility. The results of this study suggest that the alpha 1-antitrypsin in sputum may be inactivated by lysosomal proteases including elastase.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6968711     DOI: 10.1515/bchm2.1980.361.1.781

Source DB:  PubMed          Journal:  Hoppe Seylers Z Physiol Chem        ISSN: 0018-4888


  3 in total

1.  The use of monoclonal antibodies to distinguish several chemically modified forms of human alpha 1-proteinase inhibitor.

Authors:  X J Zhu; S K Chan
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

2.  Oxidative regulation of neutrophil elastase-alpha-1-proteinase inhibitor interactions.

Authors:  P J Ossanna; S T Test; N R Matheson; S Regiani; S J Weiss
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

3.  Serum and sputum alpha 2 macroglobulin in patients with chronic obstructive airways disease.

Authors:  D Burnett; R A Stockley
Journal:  Thorax       Date:  1981-07       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.